首页
>
期刊首页
>
再生生物材料(英文)
>
2026年1期
>
A smart nanocomposite bioactive ink for controlled siRNA delivery in calvarial mesenchymal stromal cells as a minimally invasive treatment for craniosynostosis
A smart nanocomposite bioactive ink for controlled siRNA delivery in calvarial mesenchymal stromal cells as a minimally invasive treatment for craniosynostosis
摘要
Craniosynostosis(CS),characterized by the premature fusion of cranial sutures,often results from aberrant activation of Fibroblast growth factor receptor 2(FGFR2),a major regulator of osteogenic differentiation in cranial mesenchyme.Despite surgical interventions,recurrence and complications remain common,underscoring the need for targeted molecular thera-pies.In this study,we developed a novel formulation of bioac-tive nanocomposite hydrogel-based ink designed for localized,sustained delivery of therapeutic small interfering RNAs(siRNAs)targeting FGFR2.The delivery system combines gela-tin methacryloyl(GelMA),a biocompatible and photo-crosslinkable hydrogel,with poly-lactic-co-glycolic acid(PLGA)nanoparticles(NPs),creating an injectable and mouldable platform with potential for future craniofacial application.Selected siRNAs achieved up to 90%FGFR2 mRNA knockdown and reduced downstream protein signalling activation,including pFGFR2(60%),pERK1/2(37%)and RUNX2(43%)in patient-derived cells.PLGA NPs demonstrated high siRNA encapsulation efficiency,efficient cytoplas-mic delivery and lysosomal escape.When embedded in GelMA and 3D-printed,the GelMA-NP system showed sustained NP reten-tion and a controlled-release profile,maintaining functional gene silencing for up to 20 days.This multifunctional platform not only supports FGFR2 modulation in CS but also holds translational promise as a customizable scaffold for delivering other bioac-tive compounds,advancing paediatric cranioplasty outcomes.
年,卷(期):
2026, 5(1)
机标分类号:
R737.33
TN929.5
R392.11
在线出版日期:
2026年6月23日